| K2P channel gating mechanisms revealed by structures of TREK-2 and a complex with Prozac YY Dong, ACW Pike, A Mackenzie, C McClenaghan, P Aryal, L Dong, ... Science 347 (6227), 1256-1259, 2015 | 324 | 2015 |
| Coronavirus proteins as ion channels: current and potential research C McClenaghan, A Hanson, SJ Lee, CG Nichols Frontiers in Immunology 11, 573339, 2020 | 83 | 2020 |
| Loss-of-Function ABCC8 Mutations in Pulmonary Arterial Hypertension MS Bohnen, L Ma, N Zhu, H Qi, C McClenaghan, C Gonzaga-Jauregui, ... Circulation: Genomic and Precision Medicine 11 (10), e002087, 2018 | 79 | 2018 |
| Bilayer-mediated structural transitions control mechanosensitivity of the TREK-2 K2P channel P Aryal, V Jarerattanachat, MV Clausen, M Schewe, C McClenaghan, ... Structure 25 (5), 708-718. e2, 2017 | 79 | 2017 |
| Polymodal activation of the TREK-2 K2P channel produces structurally distinct open states C McClenaghan, M Schewe, P Aryal, EP Carpenter, T Baukrowitz, ... The Journal of general physiology 147 (6), 497, 2016 | 76 | 2016 |
| Cantu syndrome: findings from 74 patients in the International Cantu Syndrome Registry DK Grange, HI Roessler, C McClenaghan, K Duran, K Shields, ... American Journal of Medical Genetics Part C: Seminars in Medical Genetics …, 2019 | 68 | 2019 |
| Cardiovascular consequences of KATP overactivity in Cantu syndrome Y Huang, C McClenaghan, TM Harter, K Hinman, CM Halabi, ... JCI insight 3 (15), 2018 | 50 | 2018 |
| Increased prokineticin 2 expression in gut inflammation: role in visceral pain and intestinal ion transport RP Watson, E Lilley, M Panesar, G Bhalay, S Langridge, SS Tian, ... Neurogastroenterology & Motility 24 (1), 65-e12, 2012 | 50 | 2012 |
| Glibenclamide reverses cardiovascular abnormalities of Cantu syndrome driven by KATP channel overactivity C McClenaghan, Y Huang, Z Yan, TM Harter, CM Halabi, R Chalk, ... The Journal of clinical investigation 130 (3), 1116-1121, 2020 | 43 | 2020 |
| Cantu syndrome–associated SUR2 (ABCC9) mutations in distinct structural domains result in KATP channel gain-of-function by differential mechanisms C McClenaghan, A Hanson, M Sala-Rabanal, HI Roessler, D Josifova, ... Journal of Biological Chemistry 293 (6), 2041-2052, 2018 | 42 | 2018 |
| ABCC9-related Intellectual disability Myopathy Syndrome is a KATP channelopathy with loss-of-function mutations in ABCC9 MF Smeland, C McClenaghan, HI Roessler, S Savelberg, GÅM Hansen, ... Nature communications 10 (1), 4457, 2019 | 40 | 2019 |
| Conserved functional consequences of disease-associated mutations in the slide helix of Kir6. 1 and Kir6. 2 subunits of the ATP-sensitive potassium channel PE Cooper, C McClenaghan, X Chen, A Stary-Weinzinger, CG Nichols Journal of Biological Chemistry 292 (42), 17387-17398, 2017 | 36 | 2017 |
| Pulmonary hypertension and ATP-sensitive potassium channels: paradigms and paradoxes C McClenaghan, KV Woo, CG Nichols Hypertension 74 (1), 14-22, 2019 | 32 | 2019 |
| Glibenclamide treatment in a Cantú syndrome patient with a pathogenic ABCC9 gain‐of‐function variant: Initial experience A Ma, S Gurnasinghani, EP Kirk, C McClenaghan, GK Singh, DK Grange, ... American Journal of Medical Genetics Part A 179 (8), 1585-1590, 2019 | 31 | 2019 |
| Pathophysiological consequences of KATP channel overactivity and pharmacological response to glibenclamide in skeletal muscle of a murine model of Cantù syndrome R Scala, F Maqoud, N Zizzo, A Mele, GM Camerino, FA Zito, G Ranieri, ... Frontiers in pharmacology 11, 604885, 2020 | 21 | 2020 |
| The mechanism of high-output cardiac hypertrophy arising from potassium channel gain-of-function in Cantú syndrome C McClenaghan, Y Huang, SJ Matkovich, A Kovacs, CJ Weinheimer, ... Function 1 (1), zqaa004, 2020 | 21 | 2020 |
| Kir6. 1 and SUR2B in Cantú syndrome C McClenaghan, CG Nichols American Journal of Physiology-Cell Physiology 323 (3), C920-C935, 2022 | 17 | 2022 |
| Beta‐cell excitability and excitability‐driven diabetes in adult Zebrafish islets CH Emfinger, R Lőrincz, Y Wang, NW York, SS Singareddy, JM Ikle, ... Physiological Reports 7 (11), e14101, 2019 | 16 | 2019 |
| TRPA1 agonist activity of probenecid desensitizes channel responses: consequences for screening C McClenaghan, F Zeng, JM Verkuyl Assay and Drug Development Technologies 10 (6), 533-541, 2012 | 16 | 2012 |
| Complex consequences of Cantu syndrome SUR2 variant R1154Q in genetically modified mice H Zhang, A Hanson, TS de Almeida, C Emfinger, C McClenaghan, ... JCI insight 6 (5), 2021 | 13 | 2021 |
